Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy for hepatocellular carcinoma
Zongyi Yin, Xiaowu Li
Cancer Letters (2019) Vol. 470, pp. 8-17
Closed Access | Times Cited: 218

Showing 26-50 of 218 citing articles:

Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
Yi‐Wei Xu, Xiaodong Hao, Yidan Ren, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 21
Immunotherapies for advanced hepatocellular carcinoma
Li‐Yang Sun, Kang-Jun Zhang, Ya-Ming Xie, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 18
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma
Xinrui Shi, Xia Gao, W. Liu, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 31, Iss. 4, pp. 569-590
Open Access | Times Cited: 17
Immune regulation and therapeutic application of T regulatory cells in liver diseases
Ananya Ajith, Makram Merimi, Mandana Kazem Arki, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma
Fei Li, Boshen Wang, Hao Li, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma
Yan Lu, Bo Lin, Mengsen Li
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Elephantopinolide A-P, germacrane-type sesquiterpene lactones from Elephantopus scaber induce apoptosis, autophagy and G2/M phase arrest in hepatocellular carcinoma cells
Ming Bai, Jingjie Chen, Wei Xu, et al.
European Journal of Medicinal Chemistry (2020) Vol. 198, pp. 112362-112362
Closed Access | Times Cited: 49
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Quan Rao, Min� Li, Wei Xu, et al.
Hepatology International (2020) Vol. 14, Iss. 5, pp. 765-775
Closed Access | Times Cited: 49
<p>Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma</p>
Bo Hu, Xiaobo Yang, Xinting Sang
Journal of Hepatocellular Carcinoma (2020) Vol. Volume 7, pp. 315-330
Open Access | Times Cited: 40
Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma
Jiaying Liang, Yaofeng Zhi, Wenhui Deng, et al.
PeerJ (2021) Vol. 9, pp. e11627-e11627
Open Access | Times Cited: 34
Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma
Jiwei Zhang, Tao Pan, Weiwei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 24
Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer
Po-Shuan Huang, Ling‐Yu Wang, Yiwen Wang, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 869-869
Open Access | Times Cited: 15
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
Chen Shen, Mei Li, Yujuan Duan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma
Jianye Cai, Jiancheng Wang, Chenhao Jiang, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1418-1434
Closed Access | Times Cited: 13
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review
Thomas Ruli, Ethan D. Pollack, Atul Lodh, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2042-2042
Open Access | Times Cited: 5
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment
Yanju Liu, Hongyuan Yang, Tian Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
Peter G. Hendrickson, Michael Olson, Tim Luetkens, et al.
OncoImmunology (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 36
Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma
Bingbing Shang, Jun Chen, Zhiguo Wang, et al.
PeerJ (2021) Vol. 9, pp. e12315-e12315
Open Access | Times Cited: 32
Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside
Ming‐Cheng Guan, Ming-Da Wang, Siyu Liu, et al.
World Journal of Gastrointestinal Oncology (2021) Vol. 13, Iss. 4, pp. 197-215
Open Access | Times Cited: 31
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Cheng Zhong, Yirun Li, Jing Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 30
Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition
Qingqing Xiong, Yang Bai, Run Shi, et al.
Bioactive Materials (2021) Vol. 6, Iss. 11, pp. 3744-3755
Open Access | Times Cited: 30
Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
Ji Won Han, Seung Kew Yoon
Pharmaceutics (2021) Vol. 13, Iss. 9, pp. 1387-1387
Open Access | Times Cited: 29
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
Hao-Tian Liu, Mengjie Jiang, Zhu‐Jian Deng, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 28
Immunotherapy for hepatocellular carcinoma
Mingzhen Zhou, Baorui Liu, Jie Shen
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 3, pp. 569-577
Closed Access | Times Cited: 22

Scroll to top